Armanezumab is a pathological tau protein inhibitor that specifically binds to the N-terminal domain exposed by pathological tau protein (epitope covering amino acids 4-8: PRQEF). Armanezumab is applicable to research related to Alzheimers disease, frontotemporal dementia, and Picks disease[1].
Target:
Tau Protein
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
